News

Archive: January, 2021

DOD Supports Phase III Clinical Trial Using Fostamatinib (TAVALISSE®) Against COVID-19
January 29, 2021 — The JPM CBRN Medical executed an agreement with Rigel Pharmaceuticals, Inc., to study the effectiveness of TAVALISSE® against COVID-19... MORE

Army Pfc. Christopher Elsberry, assigned to the 36th Medical Company Area Support Battalion, sanitizes a chair inside the mobile COVID-19 testing unit at the Javits Center in New York City, May 19, 2020.

DOD Supports Phase II Clinical Trials Repurposing Inhaled PUL-042 for COVID-19 Prevention and Treatment
January 26, 2021 — The JPM CBRN Medical executed an agreement with Pulmotect, Inc. to study the effectiveness of an existing compound that shows promise against COVID-19... MORE

Increased Collaboration Promotes Improved Medical Diagnostic Capabilities and Health Outcomes
January 25, 2021 — The U.S. Department of Defense (DOD) has a long-standing history of developing medical countermeasures (MCMs) to combat deadly biological threats. Vaccines, diagnostics, and therapeutics serve in a fully-layered continuum of defense capabilities that both protect before exposure as well as to inform and treat after exposure. This set of... MORE

HHS, DOD purchase additional doses of Regeneron therapeutic to treat patients with mild to moderate COVID-19
January 12, 2021 — The Department of Health and Human Services (HHS) and the Department of Defense (DOD) today announced the purchase of 1.25 million additional treatment courses of Regeneron’s investigational monoclonal antibody therapeutic, a combination of casirivimab and imdevimab, to be delivered in the first half of 2021 to treat non-hospitalized, high-risk... MORE

News Search

News Archive - Search by Year and Month

October 2023 (1)
September 2023 (5)
August 2023 (8)
July 2023 (2)
June 2023 (2)
May 2023 (3)
April 2023 (2)
March 2023 (1)
February 2023 (1)
January 2023 (1)
December 2022 (4)
November 2022 (1)
October 2022 (3)
September 2022 (5)
August 2022 (3)
July 2022 (3)
June 2022 (1)
May 2022 (1)
March 2022 (2)
February 2022 (2)
January 2022 (5)
December 2021 (1)
November 2021 (6)
October 2021 (2)
September 2021 (1)
July 2021 (1)
June 2021 (1)
May 2021 (8)
April 2021 (6)
March 2021 (2)
February 2021 (5)
January 2021 (4)
December 2020 (3)
November 2020 (1)
August 2020 (1)
July 2020 (3)
May 2020 (1)
April 2020 (1)
March 2020 (4)
February 2020 (1)
December 2019 (2)
November 2019 (2)
October 2019 (2)
September 2019 (2)
March 2019 (1)
January 2019 (2)
December 2018 (1)
October 2018 (1)
July 2018 (1)
April 2018 (1)
February 2018 (1)
December 2017 (1)
November 2017 (2)
September 2017 (1)
June 2017 (2)
January 2017 (3)
December 2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.